Oncology

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

Agreement will expand treatment options for patients with hepatitis C.

Rubraca is the latest targeted agent that treats cancers caused by specific mutations in a patient’s gene.

FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.

Pembrolizumab was associated with clinically meaningful improvements in quality of life over chemotherapy.

Researchers discovered a statistically significant link between diabetes and all-cause mortality.

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.

Xtandi plus abiraterone acetate and prednisone fails to improve progression-free survival in prostate cancer.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Attacking lung cancer cell foundation may present effective treatment option.

New findings may lead to therapeutic options for stopping lung cancer cells from spreading to different parts of the body.

Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.

Zykadia more than doubled progression-free survival in patients with ALK+ non-small cell lung cancer.

Treatment with Tecentriq helps successfully clear advanced lung cancer.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Alcohol could cause 7100 annual cancer deaths by 2035.

Blood test helps predict how aggressive lung cancer patients will respond to treatment.

Top news of the day from across the health care landscape.

Switching Tasigna elicited a long-term response rate in patients with leukemia even after discontinuing treatment.

Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.

A newly created tool can diagnose cachexia in patients with cancer and other diseases.

Interim findings further support the efficacy, safety, and tolerability of Abraxane in NSCLC.

Abraxane shows promise in hard-to-treat non-small cell lung cancer patients.

A PGY-2 Oncology Residency Director shares her advice for residents about remaining adaptable.

Individuals with a history of cigarette smoking may benefit from regular ibuprofen use.